DRW Securities’s Teva Pharmaceuticals TEVA Stock Holding History

DRW Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Sell	6,809 -18,862	-73%	-$628K	0.01%	742
2026 Q1	$773K	Buy	25,671 +13,170	+105%	+$424K	0.01%	415
2025 Q4	$390K	Sell	12,501 -5,103	-29%	-$126K	0.01%	556
2025 Q3	$357K	Buy	17,604 +3,772	+27%	+$66.3K	0.01%	766
2025 Q2	$232K	Buy	+13,832	New	+$223K	0.01%	877
2022 Q2	–	Sell	-18,576	Closed	-$174K	–	352
2022 Q1	$174K	Buy	+18,576	New	+$155K	﹤0.01%	260
2020 Q3	–	Sell	-10,717	Closed	-$132K	–	228
2020 Q2	$132K	Hold	10,717	–	–	0.01%	164
2020 Q1	$96K	Buy	+10,717	New	+$110K	﹤0.01%	262

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

DRW Securities's TEVA Position: Q2 2026 in Review

DRW Securities reduced its Teva Pharmaceuticals (TEVA) stake by 73% in Q2 2026, selling an estimated $628K and leaving 6,809 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #742.

DRW Securities first reported a position in TEVA in Q1 2020 and has held it in 8 quarters since. The position peaked at $773K in Q1 2026. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

DRW Securities held 6,809 shares of Teva Pharmaceuticals worth $231K as of Q2 2026.
DRW Securities sold 18,862 Teva Pharmaceuticals shares in Q2 2026, an estimated $628K.
Teva Pharmaceuticals made up 0.01% of DRW Securities's portfolio in Q2 2026, its #742 holding.
DRW Securities first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 8 quarters since.
DRW Securities's Teva Pharmaceuticals position peaked at $773K in Q1 2026.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.